HOME >> BIOLOGY >> NEWS
UC Riverside professor to spend year with US State Department

Dr. David A. Eastmond, a toxicologist and professor of cell biology at UC Riverside, was among five academics announced Wednesday, May 26, by Secretary of State Colin L. Powell as Jefferson Science Fellows at the U.S. Department of State.

Powell heralded the creation of the JSF program, named for the third president of the United States, Thomas Jefferson, who was both ambassador and scientist. The program will gather U.S. scientists, diplomats and policymakers to work on issues of international importance. The selected fellows are tenured scientists and engineers from U.S. colleges and universities. They are slated to report to the Office of the Science and Technology Adviser to the Secretary of State in mid-August.

Chairman of the university's Environmental Toxicology Graduate Program, Eastmond is one of five U.S. academics who make up the first class of fellows. The others are Dr. Julian Adams, University of Michigan, Dr. Bruce Averill, University of Toledo, Dr. Melba Crawford, University of Texas, Austin, and Dr. Kilidas Shetty, University of Massachusetts, Amherst.

Secretary of State Powell welcomed the inaugural class of fellows. "Over the coming year, these five individuals will be our scientific advisors and educators," Powell said in published remarks. "They'll bring fresh ideas and new perspectives to America's foreign policy. But these scientists will also get, I believe, a good deal in return. They will observe and participate in the day-to-day working of American foreign policy. They'll see how science and statecraft work together to improve the lives of people around the world. They'll gain an appreciation for the daily challenges confronting the men and women of the State Department. And, most importantly, our Jefferson Science Fellows will take their experiences with them back into our nation's classrooms and laboratories."

Eastmond said that he appreciates the opportunity to use his experience in environmental t
'"/>

Contact: Kris Lovekin
kris.lovekin@ucr.edu
909-787-2495
University of California - Riverside
27-May-2004


Page: 1 2 3

Related biology news :

1. Humans march to a faster genetic drummer than primates, UC Riverside research says
2. UC Riverside researcher takes snapshots of the movement of molecules in a billionth of a second
3. UC Riverside researchers discover new way to identify cell growth
4. UC Riverside researchers develop low-carb corn with enhanced protein and oil
5. UC Riverside researchers improve drought tolerance in plants
6. Plant sex protein identified at UC Riverside
7. UC Riverside researchers publish paper on botulism detection system
8. UC Riverside to convene conference on genetically modified organisms, Oct. 14-17, 2003
9. UC Riverside plant pathologist awarded $1 million grant to study virus assembly
10. UC Riverside study indicates mosquito coils may cause cancer
11. UC Riverside geneticist awarded $2.4 million grant by the National Science Foundation

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Riverside professor spend year with State Department

(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
(Date:4/17/2015)... Houston, TX (PRWEB) April 17, 2015 ... genomics and proteomics technologies, announced today that it ... sequencing system, an innovative multiplex PCR based targeted ... ultra-high resolution sequence analysis, that enables accurate detection ... pending Relay-PCR™ and Omega-Primer™ technologies. The company will ...
(Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
(Date:4/16/2015)... According to the 2014 Liberty ... source was ranked first among the leading causes ... lifting, pushing, pulling, holding, carrying, or throwing and ... David Round Company takes statistics like this very ... to develop and design equipment that prevents these ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: